Resverlogix Corp. (RVX.TO)
| Previous Close | 0.0550 |
| Open | 0.0550 |
| Bid | 0.0500 x 0 |
| Ask | 0.0600 x 0 |
| Day's Range | 0.0550 - 0.0550 |
| 52 Week Range | 0.0500 - 0.1200 |
| Volume | |
| Avg. Volume | 30,480 |
| Market Cap | 15.115M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileResverlogix Announces Updated Annual and Special Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024.A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and ...
NewsfileResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. In connection with the extension, Hepalink's conversion privileges have been eliminated and the interest rate has been amended from
NewsfileResverlogix Announces Change to Its Board of Directors
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal ...
